Targeted activation of HNF4α/HGF1/FOXA2 reverses hepatic fibrosis via exosome-mediated delivery of CRISPR/dCas9-SAM system

References

• 1. Zhang J, Li Y, Liu Q et al. Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells. Hepatology 73(3), 1140–1157 (2021).
  Medline CASGoogle Scholar
• 2. Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 18(3), 151–166 (2021).
  MedlineGoogle Scholar
• 3. Xu L, Wettschureck N, Bai Y, Yuan Z, Wang S. Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice. J. Hepatol. 75(1), 238–241 (2021).
  Medline CASGoogle Scholar
• 4. Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol. Aspects Med. 65, 37–55 (2019).
  Medline CASGoogle Scholar
• 5. Newberry EP, Hall Z, Xie Y et al. Liver-specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis, and hepatocellular cancer. Hepatology 74(3), 1203–1219 (2021).
  Medline CASGoogle Scholar
• 6. Gines P, Krag A, Abraldes JG, Sola E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 398(10308), 1359–1376 (2021).
  MedlineGoogle Scholar
• 7. Friedman SL, Pinzani M. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology 75(2), 473–488 (2022).
  Medline CASGoogle Scholar
• 8. Oh SH, Swiderska-Syn M, Jewell ML, Premont RT, Diehl AM. Liver regeneration requires Yap1-TGFbeta-dependent epithelial-mesenchymal transition in hepatocytes. J. Hepatol. 69(2), 359–367 (2018).
  Medline CASGoogle Scholar
• 9. Michalopoulos GK, Bhushan B. Liver regeneration: biological and pathological mechanisms and implications. Nat. Rev. Gastroenterol. Hepatol. 18(1), 40–55 (2021).
  MedlineGoogle Scholar
• 10. Campana L, Esser H, Huch M, Forbes S. Liver regeneration and inflammation: from fundamental science to clinical applications. Nat. Rev. Mol. Cell Biol. 22(9), 608–624 (2021).
  Medline CASGoogle Scholar
• 11. Zhu M, Lu T, Jia Y et al. Somatic mutations increase hepatic clonal fitness and regeneration in chronic liver disease. Cell 177(3), 608–621 e612 (2019).
  Medline CASGoogle Scholar
• 12. Duan JL, Ruan B, Song P et al. Shear stress-induced cellular senescence blunts liver regeneration through Notch-sirtuin 1-P21/P16 axis. Hepatology 75(3), 584–599 (2022).
  Medline CASGoogle Scholar
• 13. Liu Y, Xu N, Ji H. Reply to: “Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice.” J. Hepatol. 75(1), 241–243 (2021).
  Medline CASGoogle Scholar
• 14. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14(7), 397–411 (2017).
  Medline CASGoogle Scholar
• 15. Trivedi P, Wang S, Friedman SL. The power of plasticity – metabolic regulation of hepatic stellate cells. Cell Metab. 33(2), 242–257 (2021).
  Medline CASGoogle Scholar
• 16. Li F, Huangyang P, Burrows M et al. FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome. Nat. Cell Biol. 22(6), 728–739 (2020).
  MedlineGoogle Scholar
• 17. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut 64(5), 830–841 (2015).
  Medline CASGoogle Scholar
• 18. Yang W, He H, Wang T et al. Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis in mice. Hepatology 74(5), 2774–2790 (2021).
  Medline CASGoogle Scholar
• 19. Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68(2), 238–250 (2018).
  Medline CASGoogle Scholar
• 20. Dat NQ, Thuy LTT, Hieu VN et al. Hexa histidine-tagged recombinant human cytoglobin deactivates hepatic stellate cells and inhibits liver fibrosis by scavenging reactive oxygen species. Hepatology 73(6), 2527–2545 (2021).
  Medline CASGoogle Scholar
• 21. Lv F, Li N, Kong M et al. CDKN2a/p16 antagonizes hepatic stellate cell activation and liver fibrosis by modulating ROS levels. Front. Cell Dev. Biol. 8, 176 (2020).
  MedlineGoogle Scholar
• 22. Li Y, Zhang Y, Chen T et al. Role of aldosterone in the activation of primary mice hepatic stellate cell and liver fibrosis via NLRP3 inflammasome. J. Gastroenterol. Hepatol. 35(6), 1069–1077 (2020).
  Medline CASGoogle Scholar
• 23. Choi WM, Ryu T, Lee JH et al. Metabotropic glutamate receptor 5 in natural killer cells attenuates liver fibrosis by exerting cytotoxicity to activated stellate cells. Hepatology 74(4), 2170–2185 (2021).
  Medline CASGoogle Scholar
• 24. Yang L, Han B, Zhang M et al. Activation of BK channels prevents hepatic stellate cell activation and liver fibrosis through the suppression of TGFbeta1/SMAD3 and JAK/STAT3 profibrotic signaling pathways. Front. Pharmacol. 11, 165 (2020).
  Medline CASGoogle Scholar
• 25. Wang Q, Wei S, Zhou H et al. MicroRNA-98 inhibits hepatic stellate cell activation and attenuates liver fibrosis by regulating HLF expression. Front. Cell Dev. Biol. 8, 513 (2020).
  MedlineGoogle Scholar
• 26. Wang L, Wang Y, Quan J. Exosomes derived from natural killer cells inhibit hepatic stellate cell activation and liver fibrosis. Hum. Cell 33(3), 582–589 (2020).
  Medline CASGoogle Scholar
• 27. Chen W, Yan X, Yang A, Xu A, Huang T, You H. miRNA-150-5p promotes hepatic stellate cell proliferation and sensitizes hepatocyte apoptosis during liver fibrosis. Epigenomics 12(1), 53–67 (2020).
  CASGoogle Scholar
• 28. Arab JP, Cabrera D, Sehrawat TS et al. Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12. J. Hepatol. 73(1), 149–160 (2020).
  Medline CASGoogle Scholar
• 29. Zhang S, Shen J, Li D, Cheng Y. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing. Theranostics 11(2), 614–648 (2021).
  Medline CASGoogle Scholar
• 30. Wang X, Li X, Ma Y et al. Inhibition mechanisms of CRISPR-Cas9 by AcrIIA17 and AcrIIA18. Nucleic Acids Res. 50(1), 512–521 (2022).
  Medline CASGoogle Scholar
• 31. Van Hees M, Slott S, Hansen AH, Kim HS, Ji HP, Astakhova K. New approaches to moderate CRISPR-Cas9 activity: addressing issues of cellular uptake and endosomal escape. Mol. Ther. 30(1), 32–46 (2022).
  Medline CASGoogle Scholar
• 32. Tirado-Gonzalez I, Czlonka E, Nevmerzhitskaya A et al. Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. Leukemia 35(1), 294 (2021).
  Medline CASGoogle Scholar
• 33. Kondrashov A, Mohd Yusof NAN, Hasan A et al. CRISPR/Cas9-mediated generation and analysis of N terminus polymorphic models of beta2AR in isogenic hPSC-derived cardiomyocytes. Mol. Ther. Methods Clin. Dev. 20, 39–53 (2021).
  Medline CASGoogle Scholar
• 34. Lin-Shiao E, Pfeifer WG, Shy BR et al. CRISPR-Cas9-mediated nuclear transport and genomic integration of nanostructured genes in human primary cells. Nucleic Acids Res. 50(3), 1256–1268 (2022).
  MedlineGoogle Scholar
• 35. Bhattacharjee G, Gohil N, Khambhati K et al. Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. J. Control. Release 343, 703–723 (2022).
  Medline CASGoogle Scholar
• 36. Singh K, Evens H, Nair N et al. Efficient in vivo liver-directed gene editing using CRISPR/Cas9. Mol. Ther. 26(5), 1241–1254 (2018).
  Medline CASGoogle Scholar
• 37. Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181(1), 136–150 (2020).
  Medline CASGoogle Scholar
• 38. Sanchez-Navarro M. Advances in peptide-mediated cytosolic delivery of proteins. Adv. Drug Deliv. Rev. 171, 187–198 (2021).
  Medline CASGoogle Scholar
• 39. Zhang HX, Zhang Y, Yin H. Genome editing with mRNA encoding ZFN, TALEN, and Cas9. Mol. Ther. 27(4), 735–746 (2019).
  Medline CASGoogle Scholar
• 40. Yan J, Kang DD, Turnbull G, Dong Y. Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer. Adv. Drug Deliv. Rev. 180, 114042 (2022).
  Medline CASGoogle Scholar
• 41. Kim G, Lee Y, Ha J, Han S, Lee M. Engineering exosomes for pulmonary delivery of peptides and drugs to inflammatory lung cells by inhalation. J. Control. Release 330, 684–695 (2021).
  Medline CASGoogle Scholar
• 42. Ferguson S, Yang KS, Weissleder R. Single extracellular vesicle analysis for early cancer detection. Trends Mol. Med. 28(8), 681–692 (2022).
  Medline CASGoogle Scholar
• 43. Bie N, Yong T, Wei Z, Gan L, Yang X. Extracellular vesicles for improved tumor accumulation and penetration. Adv. Drug Deliv. Rev. 188, 114450 (2022).
  Medline CASGoogle Scholar
• 44. Jiao Y, Lu W, Xu P et al. Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure. Hepatol. Int. 15(4), 957–969 (2021).
  MedlineGoogle Scholar
• 45. Zhao L, Wang H, Fu J et al. Microfluidic-based exosome isolation and highly sensitive aptamer exosome membrane protein detection for lung cancer diagnosis. Biosens. Bioelectron. 214, 114487 (2022).
  Medline CASGoogle Scholar
• 46. Paskeh MDA, Entezari M, Mirzaei S et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J. Hematol. Oncol. 15(1), 83 (2022).
  Medline CASGoogle Scholar
• 47. Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics 11(7), 3183–3195 (2021).
  Medline CASGoogle Scholar
• 48. Chen H, Sun T, Jiang C. Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy. J. Control. Release 348, 572–589 (2022).
  Medline CASGoogle Scholar
• 49. Yang T, Poenisch M, Khanal R et al. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J. Hepatol. 75(6), 1420–1433 (2021).
  Medline CASGoogle Scholar
• 50. Park MR, Wong MS, Arauzo-Bravo MJ et al. Oct4 and Hnf4alpha-induced hepatic stem cells ameliorate chronic liver injury in liver fibrosis model. PLOS ONE 14(8), e0221085 (2019).
  Medline CASGoogle Scholar
• 51. Wang W, Yao LJ, Shen W et al. FOXA2 alleviates CCl₄-induced liver fibrosis by protecting hepatocytes in mice. Sci. Rep. 7(1), 15532 (2017).
  MedlineGoogle Scholar
• 52. Lainscek D, Kadunc L, Keber MM, Bratkovic IH, Romih R, Jerala R. Delivery of an artificial transcription regulator DCAS9-VPR by extracellular vesicles for therapeutic gene activation. ACS Synth. Biol. 7(12), 2715–2725 (2018).
  Medline CASGoogle Scholar
• 53. Duan L, Xu L, Xu X et al. Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale 13(3), 1387–1397 (2021).
  Medline CASGoogle Scholar
• 54. Kozumi K, Kodama T, Murai H et al. Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis. Hepatology 74(5), 2452–2466 (2021).
  Medline CASGoogle Scholar
• 55. Hou LS, Zhang YW, Li H et al. The regulatory role and mechanism of autophagy in energy metabolism-related hepatic fibrosis. Pharmacol. Ther. 234, 108117 (2022).
  Medline CASGoogle Scholar
• 56. Chen L, Guo P, Li W et al. Perturbation of specific signaling pathways is involved in initiation of mouse liver fibrosis. Hepatology 73(4), 1551–1569 (2021).
  Medline CASGoogle Scholar
• 57. Coll M, Perea L, Boon R et al. Generation of hepatic stellate cells from human pluripotent stem cells enables in vitro modeling of liver fibrosis. Cell Stem Cell 23(1), 101–113 e107 (2018).
  Medline CASGoogle Scholar
• 58. Van Grunsven LA. 3D in vitro models of liver fibrosis. Adv. Drug Deliv. Rev. 121, 133–146 (2017).
  Medline CASGoogle Scholar
• 59. Matsuo M, Murata S, Hasegawa S, Hatada Y, Ohtsuka M, Taniguchi H. Novel liver fibrosis model in Macaca fascicularis induced by thioacetamide. Sci. Rep. 10(1), 2450 (2020).
  Medline CASGoogle Scholar
• 60. Lu ZN, Niu WX, Zhang N et al. Pantoprazole ameliorates liver fibrosis and suppresses hepatic stellate cell activation in bile duct ligation rats by promoting YAP degradation. Acta. Pharmacol. Sin. 42(11), 1808–1820 (2021).
  Medline CASGoogle Scholar
• 61. Tao L, Ma W, Wu L et al. Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5/Smad signalling. Gut 68(12), 2214–2227 (2019).
  Medline CASGoogle Scholar
• 62. Chen H, Gan Q, Yang C et al. Correction to: a novel role of glutathione S-transferase A3 in inhibiting hepatic stellate cell activation and rat hepatic fibrosis. J. Transl. Med. 18(1), 182 (2020).
  Medline CASGoogle Scholar
• 63. Zhang Z, Wen H, Weng J et al. Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway. Cell Cycle 18(18), 2239–2254 (2019).
  Medline CASGoogle Scholar
• 64. Wei S, Wang Q, Zhou H et al. miR-455-3p alleviates hepatic stellate cell activation and liver fibrosis by suppressing HSF1 expression. Mol. Ther. Nucleic Acids 16, 758–769 (2019).
  Medline CASGoogle Scholar
• 65. Deng X, Zhang X, Li W et al. Chronic liver injury induces conversion of biliary epithelial cells into hepatocytes. Cell Stem Cell 23(1), 114–122, e113 (2018).
  Medline CASGoogle Scholar
• 66. Wang S, Kim J, Lee C et al. Tumor necrosis factor-inducible gene 6 reprograms hepatic stellate cells into stem-like cells, which ameliorates liver damage in mouse. Biomaterials 219, 119375 (2019).
  Medline CASGoogle Scholar
• 67. Arriola Benitez PC, Pesce Viglietti AI, Gomes MTR et al. Brucella abortus infection elicited hepatic stellate cell-mediated fibrosis through inflammasome-dependent IL-1beta production. Front. Immunol. 10, 3036 (2019).
  MedlineGoogle Scholar
• 68. Luo N, Li J, Chen Y et al. Hepatic stellate cell reprogramming via exosome-mediated CRISPR/DCAS9-VP64 delivery. Drug Deliv. 28(1), 10–18 (2021).
  Medline CASGoogle Scholar
• 69. Schuppan D, Ashfaq-Khan M, Yang AT, Kim YO. Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol. 68, 435–451 (2018).
  MedlineGoogle Scholar
• 70. Brody H. Gene therapy. Nature 564(7735), S5 (2018).
  Medline CASGoogle Scholar
• 71. High KA, Roncarolo MG. Gene Therapy. N. Engl. J. Med. 381(5), 455–464 (2019).
  Medline CASGoogle Scholar
• 72. Weber M, Mera P, Casas J et al. Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD. FASEB J. 34(9), 11816–11837 (2020).
  Medline CASGoogle Scholar
• 73. Dalwadi DA, Torrens L, Abril-Fornaguera J et al. Liver injury increases the incidence of HCC following AAV gene therapy in mice. Mol. Ther. 29(2), 680–690 (2021).
  Medline CASGoogle Scholar
• 74. De Jong YP, Herzog RW. Liver gene therapy and hepatocellular carcinoma: a complex web. Mol. Ther. 29(4), 1353–1354 (2021).
  MedlineGoogle Scholar
• 75. Van Der Weyden L, Jonkers J, Adams DJ. The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice. Curr. Opin. Genet. Dev. 66, 57–62 (2021).
  MedlineGoogle Scholar
• 76. Li Z, Zhou X, Wei M et al. In vitro and in vivo RNA Inhibition by CD9-HuR functionalized exosomes encapsulated with miRNA or CRISPR/DCAS9. Nano Lett 19(1), 19–28 (2019).
  Medline CASGoogle Scholar
• 77. Li Z, Zhou X, Gao X et al. Fusion protein engineered exosomes for targeted degradation of specific RNAs in lysosomes: a proof-of-concept study. J. Extracell. Vesicles 9(1), 1816710 (2020).
  Medline CASGoogle Scholar
• 78. Chen R, Huang H, Liu H et al. Friend or foe? Evidence indicates endogenous exosomes can deliver functional gRNA and Cas9 protein. Small 15(38), e1902686 (2019).
  MedlineGoogle Scholar
• 79. Ye Y, Zhang X, Xie F et al. An engineered exosome for delivering sgRNA: Cas9 ribonucleoprotein complex and genome editing in recipient cells. Biomater. Sci. 8(10), 2966–2976 (2020).
  Medline CASGoogle Scholar
• 80. Xu M, Xu HH, Lin Y et al. LECT2, a ligand for Tie1, plays a crucial role in liver fibrogenesis. Cell 178(6), 1478–1492, e1420 (2019).
  Medline CASGoogle Scholar
• 81. He X, Sun Y, Lei N et al. MicroRNA-351 promotes schistosomiasis-induced hepatic fibrosis by targeting the vitamin D receptor. Proc. Natl. Acad. Sci. USA 115(1), 180–185 (2018).
  Medline CASGoogle Scholar
• 82. Gulei D, Berindan-Neagoe I. Activation of necroptosis by engineered self tumor-derived exosomes loaded with CRISPR/Cas9. Mol. Ther. Nucleic Acids 17, 448–451 (2019).
  Medline CASGoogle Scholar
• 83. Konermann S, Brigham MD, Trevino AE et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517(7536), 583–588 (2015).
  Medline CASGoogle Scholar